Business Context and Reporting Period
This Form 8-K is a current report filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on September 16, 2019, covering events occurring on September 10, 2019. The filing details significant changes to the company's executive leadership team and related compensatory arrangements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and executive compensation terms.
Material Changes
- Leadership Transition: Mark J. Rosenblum was appointed Executive Vice President Finance and Interim Chief Financial Officer, effective September 10, 2019. He serves as the principal financial officer.
- Role Reassignment: Scott Jordan transitioned from Chief Financial Officer to Chief Business Officer, effective September 10, 2019.
- Employment Agreements: The Company amended employment agreements for CEO David J. Arthur and the newly appointed Chief Business Officer Scott Jordan, assigning rights and obligations from the private entity (Salarius Pharmaceuticals, LLC) to the public company.
- Stock Option Grants: On September 10, 2019, the Compensation Committee granted stock options to executive officers with an exercise price of $8.00 per share (the closing price on the grant date). The options vest over 4 years (25% on September 30, 2020, and the remainder quarterly).
Compensation and Outlook
Compensatory Arrangements for Mark J. Rosenblum:
- Base Salary: Initial annual base salary of $265,000.
- Performance Bonuses: A minimum bonus of $19,300 payable by March 1, 2020 (contingent on employment through Dec 31, 2019) and a minimum of $14,500 payable by May 1, 2020 (contingent on employment through March 31, 2020).
- Stock Options: Granted 19,008 shares subject to option.
- Previous Consulting: Prior to this appointment, Mr. Rosenblum was a consultant receiving $28,000 per month; this agreement was terminated upon his employment.
Stock Option Grants Summary:
| Officer | Title | Shares Subject to Option |
|---|---|---|
| David J. Arthur | Chief Executive Officer | 30,000 |
| Scott Jordan | Chief Business Officer | 10,000 |
| Mark J. Rosenblum | EVP Finance / Interim CFO | 19,008 |
Outlook and Risks: The filing does not provide specific business outlook, guidance, or risk factors beyond the standard disclosure of executive compensation and employment terms.
Investor Verification Checklist
- Verify the exact vesting schedule and performance conditions for the stock options granted to the CEO, CBO, and Interim CFO.
- Confirm the total cash compensation impact of Mr. Rosenblum's appointment, including the transition from his prior consulting fees to his new salary and bonus structure.
- Review the attached Exhibit 10.1 (Offer Letter) and Exhibits 10.3/10.5 (Employment Amendments) for full legal terms regarding termination and severance.
- Note that the filing references "Salarius Pharmaceuticals, Inc." despite the user prompt mentioning "Decoy Therapeutics Inc."; ensure the correct entity is being analyzed.